← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors
etanercept
L04AB01
Forms & Strengths
- 25mg and 50mg prefilled syringes
- 25mg and 50mg lyophilized powder vials for injection
- 50mg prefilled autoinjectors
Adult Dosing
- 50mg subcutaneously once weekly
- 25mg subcutaneously twice weekly
- dosage may vary based on specific disease being treated
Pediatric Dosing
- 0.8mg/kg subcutaneously once weekly for patients with juvenile idiopathic arthritis
- dosage for pediatric patients with plaque psoriasis is based on weight
- maximum dose not to exceed 50mg per week
Indications
- moderate to severe rheumatoid arthritis
- psoriatic arthritis
- ankylosing spondylitis
- plaque psoriasis
- juvenile idiopathic arthritis
Mechanism of Action
- tumor necrosis factor-alpha (TNF-alpha) inhibitor
- binds to TNF-alpha and prevents interaction with cell surface receptors
- reduces inflammatory response
Contraindications
- severe infections (e.g., sepsis, TB)
- history of hypersensitivity to etanercept
- live virus vaccination in patients on etanercept
Adverse Reactions
- injection site reactions
- upper respiratory infections
- headache
- nausea
- increased risk of serious infections
Drug Interactions
- abatacept: increased risk of serious infections
- anakinra: increased risk of serious infections
- live virus vaccines: avoid use due to increased risk of infection
- other TNF inhibitors and biological DMARDs: not recommended for concomitant use
Curated Content: Needs Vetting Before Put to Clinical Use